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requires each drug to be listed in the national drug formulary according to a law 
passed in 2002. The objective of this law was to certify not only the safety profile 
of every new drug, but also its economical benefits based on a 
pharmacoeconomical study that must be presented for evaluation. OBJECTIVES: 
To analyze if the expenditure made by the IMSS in 2011 used the cost-
effectiveness criteria based on the drugs listed in the national formulary. 
METHODS: Six high resource consuming diseases in the country were selected 
together with their respective prescribed treatments. Each prescribed treatment 
was classified according to three parameters: - Less expensive treatment - Most 
expensive treatment - Cost-effective treatment Prices of each treatment and its 
total expenditure were obtained through the institute’s official purchase portal. 
Pharmacoeconomical studies needed to obtain the cost effective treatment were 
already evaluated for drug's inclusion in the national formulary. Results were 
analyzed to evaluate the expenditure's nature. RESULTS: In a half of the studied 
diseases, the expenditure on other none cost-effective treatments represented at 
least 50% more than for the cost-effective ones. The total expenditure on the 
studied cases was US $226,881,190.64. From these consumed resources, 33.54% 
was used to buy other non cost-effective drugs. From the observed purchases 
made, 40% were direct adjudications not open to competition. CONCLUSIONS: 
Even though every new drug is being evaluated since year 2002 to show its 
economical benefits, the studied institution in not fully using the cost-
effectiveness criteria to buy its drugs in Mexico, even in some of the most 
resource consuming diseases.  
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OBJECTIVES: This paper examines which families bear the heaviest financial 
burden from recent changes in cost-sharing provisions of employment-based 
health insurance among different socioeconomic and health statuses 
characteristics. METHODS: The data source for this study is the Medical 
Expenditure Panel Survey (MEPS), a nationally representative household panel 
survey conducted by AHRQ in 2001 and 2005. We apply semi-log regression 
model to identify factors that help to explain the variation in family out-of-
pocket spending (FOOPSPD) and quantile regression to describe how FOOPSPD 
has changed throughout the out-of-pocket spending distribution and thus to 
assess the effectiveness of risk protection from holding employment-based 
health insurance. Additionally, a quantile regression is used to decompose the 
difference in FOOPSPD distribution into changes in family characteristics and 
changes in structural factors. RESULTS: Between 2001 and 2005, average 
FOOPSPD had significantly increased by 22%. Econometric findings showed that 
having one more health conditions increased FOOPSPD by up to 11%. 
Additionally, the biggest increase in FOOPSPD occurred among families who 
were in the top quantiles of the FOOPSPD distribution with certain health 
conditions. Among 11 major high-cost health conditions, having COPD or asthma 
and/or hypertension were the two key conditions that triggered the biggest 
increases in FOOPSPD burdens. The results from the decomposition analysis 
revealed that more than 80% of changes in FOOPSPD were associated with the 
structural changes. CONCLUSIONS: Families who relied more on health care 
because of one or more family members’ existing health conditions were most 
affected by changes in cost sharing during the study period. In addition, 
decreases in the “return” to risk protection from holding private health 
insurance, in terms of increased exposure to premium payments and out-of-
pocket medical spending, occurred primarily for families who spent the least and 
the most out-of-pocket for medical care experienced greater increase in 
FOOPSPD.  
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OBJECTIVES: Today, we observe quite a disruption over most countries in value 
appreciation of new drugs, that is making historical data used for forecasting 
pharmaceutical expenditure poorly reliable. Forecasting methods rarely 
addressed uncertainty. The objective of this project was to propose a 
methodology to perform pharmaceutical expenditure forecast integrating 
expected policy changes and uncertainty (developed for the European 
Commission: “EU Pharmaceutical expenditure forecast” http://ec.europa.eu/ 
health/healthcare/key_documents/index_en.htm METHODS: 1) Identify all 
pharmaceuticals going off-patent and new branded medicinal products, over 5-
year forecasting period, in seven EU Member States; 2) Develop a model to 
estimate direct and indirect impact (based on health policy and clinical experts) 
on savings of generics and biosimilars. Inputs were originator sales value, patent 
expiry date, time to launch after marketing authorization, price discount, 
penetration rate, time to peak sales, impact on brand price; 3) Develop a model 
for new entrants, which estimated sales progression in competitive 
environment. Clinical expected benefits as well as commercial potential were 
assessed for each product by clinical experts. Inputs were development phase, 
marketing authorization dates, orphan condition, market size, competitors; 4) 
Analyze separately budget impact of products going off-patent and new entrants 
according to several perspectives, distribution chain and outcomes; and 5) 
Address uncertainty surrounding estimations via deterministic and probabilistic 
sensitivity analysis. RESULTS: This methodology allowed 1) to identify main 
parameters impacting pharmaceutical expenditure forecast varying across 
countries: generics discounts and penetration, brand price after patent loss, 
reimbursement rate, penetration of biosimilars and discount price, distribution 
chain, time to peak sales for new entrants; 2) to define probability of occurrence 
of a pre-determined impact thanks to probabilistic analysis; and 3) to test 
different pricing and reimbursement policy decisions on health expenditures. 
CONCLUSIONS: This methodology is independent of historical data and appears 
to be highly flexible and adapted to test robustness and provide probablisitic 
analysis to support policy decision making.  
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OBJECTIVES: Many clinical measures and patient-reported quality-of-life scores 
correlate with health care resource use, but their relative predictive value is 
understudied. This analysis compares a well-established physical-health-related 
quality of life measure against comorbidity status and current medical visits in 
their ability to predict the number of doctor visits three months later. METHODS: 
Data are drawn from a 2009 study of a general US representative sample in 
which a subset were reinterviewed after approximately 3 months (n=470). Study 
measures included a comorbidity checklist, a self-reported count of medical 
visits in the preceding four weeks, and the SF-36 or SF-12 physical component 
summary (PCS) measure. We constructed three logistic regression models 
estimating the probability of higher resource use (self-report of 2+ medical visits 
in the past four weeks vs. 1 or none) after three months. Model 1 included the 
number of comorbidities (none; 1; 2-3; 4+) and resource use (count of medical 
visits) at baseline as independent variables. Model 2 included just PCS at 
baseline, and model 3 included all predictors from models 1 and 2. RESULTS: 
Models 1 (AUC=0.77, pseudo-R2=0.16) and 2 (AUC=0.76, pseudo-R2=0.14) have 
roughly the same explanatory power, suggesting that PCS has predictive ability 
similar to counts of comorbidities and medical visits. For example, a 5-point 
lower PCS at baseline is associated with a 50% increase in the odds of having 2+ 
medical visits three months later (Model 2), an association similar to that of one 
more medical visit at baseline or being in a higher comorbidity count category 
(Model 1). Model 3 (AUC=0.80, pseudo-R2=0.19) improves somewhat on both 
models. CONCLUSIONS: Our results suggest that as compared to comorbidity 
counts and number of medical visits, PCS alone has similar ability to predict 
having 2+ doctor visits during a four week period three months later.  
 
PHP73  
RACIAL DISPARITY IN HOSPITAL INPATIENT COST: HOMELESS VERSUS NON-
HOMELESS PATIENTS  
Wong H, Karaca Z 
Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA  
OBJECTIVES: There is no study empirically comparing the racial disparity in 
hospital inpatient cost between homeless and non-homeless patients. This paper 
compares hospital inpatient costs between homeless and non-homeless patients 
across race groups. This paper further provides comprehensive descriptive 
information on patient characteristics, insurance coverage, disease prevalence, and 
severity of illness for homeless patients and non-homeless patients by race groups. 
METHODS: We employed propensity score matching to create two cohorts, where 
inpatient hospital visits between homeless and non-homeless patients were 
matched based on patients’ demographics and clinical information, and hospital 
types. These new similar cohorts were then used to compare the cost per hospital 
visit between homeless and non-homeless patients through multivariate regression 
analysis. The Healthcare Cost and Utilization Project (HCUP) State Inpatient 
Databases (SID) for 2009 were used. Data were drawn from 579 hospitals reporting 
data on homelessness in Arizona, California, Colorado, Florida, Georgia, 
Massachusetts, Missouri, New York, Pennsylvania, and Wisconsin. SID provide 
detailed diagnoses, procedures, total charges and patient demographics including 
homelessness. We linked SID files with American Hospital Association Annual 
Survey Database and Area Resource File to obtain hospital and area level 
characteristics. RESULTS: We find significant variations in hospital inpatient costs 
between homeless and non-homeless patients across race groups. Our risk adjusted 
results show that homeless patients generally have lower inpatient costs when 
compared to non-homeless patients. We find that homeless white patients have 
higher inpatient costs and non-homeless white patients have lower inpatient costs 
when compared to their homeless non-white and non-homeless non-white 
counterparts respectively. We also find that the majority of homeless children at 
hospital inpatient departments are non-white. In addition, about a third of all 
inpatient hospital visits by white homeless patients are for female individuals. 
CONCLUSIONS: This study provides comprehensive empirical evidence for racial 
disparity in hospital inpatient costs between homeless and non-homeless patients.  
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OBJECTIVES: To develop and test a measure of outpatient prescription 
medication utilization (medication exposure measure – MEM) that may be 
coupled with the CMS-HCC and CMS-RxHCC methodologies to improve CMS risk-
adjusted capitated payments to Medicare Part C and Part D plans. The MEM 
should be more difficult for health plans and providers to manipulate compared 
with unique drug or prescription counts. MEM is operationalized as the average 
number of unique drugs that an individual possesses over a specified time 
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period. METHODS: The 5% Medicare national sample Parts A, B, & D (n=1,229,698) 
was used to estimate ordinary least squares regression models for prospective 
community payment to predict year-2 (2008) annualized medical (CMS-HCC) and 
pharmacy (CMS-RxHCC) expenditures from year-1 (2007) demographics, CMS 
model inputs, and the MEM. Gamma-distributed, log-linked generalized linear 
models were estimated for zero-inflated medical expenditure outcomes. OLS 
models were also estimated using truncated and log-transformed expenditures. 
RESULTS: The CMS-HCC model (OLS R2=0.0698) was only marginally improved 
by the addition of MEM (R2=0.0706). The CMS-RxHCC model (R2=0.1485; Grouped 
R2=0.3696) was markedly improved by the addition of MEM (R2=0.2489; Grouped 
R2=0.7692). Further, the predictive ratios for pharmacy expenditure deciles show 
that the CMS-RxHCC+MEM model more accurately predicts in 8 out of 10 deciles 
compared to the CMS-RxHCC alone. CONCLUSIONS: Although adding MEM to 
the CMS-HCC models used to predict medical expenditures does not appear to be 
a useful method of enhancing risk-adjusted payments, the MEM performed 
particularly well with the CMS-RxHCC model, predicting year-2 pharmacy 
expenditures. Pharmacy expenditures are generally less variable compared to 
medical expenditures, making improvements to prediction more difficult for 
medical models. Incorporating the MEM into Medicare Part D risk-adjustment 
models (CMS-RxHCC) would improve risk-adjusted capitated payments from 
both the perspectives of CMS and the health plans and mitigate adverse risk 
selection.  
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OBJECTIVES: Turkey has accomplished remarkable improvements in terms of 
health status particularly after the implementation of the Health Transformation 
Program (HTP). Within the scope of HTP, the number of people covered by public 
health insurance, the number of hospital visits and also the number of physician 
consultation per capita has increased and disparities of benefit package between 
different sick funds have been unified. As a result, total health care expenditures 
have increased at a large extent. The aim of this study is to evaluate the rates of 
increases in the expenditures of Social Security Institution (SSI) in terms of 
pharmaceutical and treatment expenditures between 2005 and 2011. METHODS: 
Databases of SSI, IMS, Ministry of Health and AIFD have been searched for the 
period of 2005 to 2011. Rates of increase in the health expenditures, number of 
people covered by public health insurance, hospital visits and the number of 
physician consultation per capita have been evaluated and compared. RESULTS: 
Between 2005 and 2011, coverage of public health insurance has risen from 89 to 
96, physician consultation per capita has increased 63.8%, total health 
expenditures of SSI have increased 18% with a 23% increase in treatment 
expenditures and 12% increase in pharmaceutical expenditures. CONCLUSIONS: 
As a result of increase in the coverage of public health insurance and the number 
of hospital visits, treatment expenditures have risen at a large extent. But on the 
other hand, pharmaceutical expenditures’ increase rate was not at the same 
level. The main reasons are the global budget policy and the increases at the 
mandatory institutional discounts, which are being used as a major cost 
containment tool. Despite the success in the containment of pharmaceutical 
expenditures, any major cost containment policy for treatment expenditures 
haven’t been implicated, and in addition treatment expenditures are continuing 
to rise.  
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OBJECTIVES: The German Pharmaceutical Market Restructuring Act (AMNOG) 
was implemented January 2011 and heralded as one of the most important 
European health care reforms to impact the pharmaceutical industry. Two years 
into its implementation the industry is still adapting and learning to navigate the 
new process effectively. This research assessed the impact of the AMNOG reform 
since January 2011 to inform new product development and launch strategies. 
METHODS: To identify the criteria for successful benefit assessment outcomes 
and their relative importance in justifying price premiums, the benefit 
assessment dossiers submitted to-date were analysed in a systematic approach. 
Findings were then validated through in-depth interviews with national level 
stakeholders. RESULTS: As of January 2013, 29 products have been launched in 
Germany since the AMNOG reform: five achieved a considerable additional 
benefit, ten received a minor additional benefit and three received an 
unquantifiable additional benefit. However, almost half of the products 
submitted for benefit assessment were not granted any additional benefit, 
indicating that two years after the implementation of the AMNOG reform, 
manufacturers are still adapting to the changing payer environment. Reasons for 
unsuccessful benefit assessment outcomes point to the importance of building a 
dialogue with the G-BA before dossier submission and understanding the G-BA’s 
criteria for comparator selection. They also highlight the importance of opting 
for a clinical trial design, acceptable within IQWiG’s benefit assessment 
methodology, amenable to robust comparative studies with the chosen 
comparator and long-term data collection. CONCLUSIONS: The new German 
HTA process is still an evolving process and it is important to learn from the 
completed benefit assessments and price negotiations. This understanding will 
help secure successful outcomes for products currently in development and 
patient access to novel therapies, not only in Germany, but in other countries, 
which continue to look at the German HTA model for reference.  
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OBJECTIVES: Relational continuity of care (COC) refers to the quality and 
duration of the relationship between a patient and provider. We aimed to 
determine whether increased COC is associated with decreased health care 
utilization in patients with chronic conditions. METHODS: We searched 
MEDLINE, EMBASE, CINAHL and the Cochrane Library from 2002 to December 
2011 to identify studies comparing outcomes in patients with high, medium, and 
low COC. Chronic disease cohorts were constructed using administrative 
databases from Ontario, Canada. Resource use and costs for each condition were 
calculated over five years and utility values were identified in the literature; 
estimates of clinical effect were applied to each cohort. The expected cost (2012 
Canadian dollars) and QALY gain of improving continuity was explored in a 
sensitivity analysis. RESULTS: Thirteen observational studies were included in 
the systematic review. All assessed continuity using administrative data to 
measure visits to primary care providers. Results were not pooled due to 
variability in COC indices and patient populations. However, across all cohorts 
people with high COC had significantly fewer hospitalizations and emergency 
department visits compared to people with low and medium continuity. As a 
result, people with high continuity incur fewer health care costs compared to 
those with lower continuity . It is likely that interventions designed to improve 
COC would represent value for money, even if only marginally effective. 
CONCLUSIONS: These initiatives could take the form of policy decisions 
governing the financing and delivery of health care in the community. Such 
changes may have far-reaching consequences for patients and providers 
throughout the system; more research in this area is needed. The literature was 
limited by an absence of evidence in family health teams and among providers 
who are not physicians.  
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OBJECTIVES: This study identifies factors that influence physicians’ use of 
medical resources. METHODS: We used the Healthcare Cost and Utilization 
Project (HCUP) State Inpatient Databases (SID), the American Hospital 
Association Annual Survey Database, and the Area Resource File in this analysis. 
Our hospital data for 2008 were drawn from Arizona and Florida, and physician 
information was obtained from medical boards of each state where we used 
physicians’ license numbers to register each hospital inpatient visit to a 
physician. Over 2.5 million inpatient records were used in the analysis. We 
employed linear cost models using all hospital inpatient stays registered to 
physicians for whom we had information on observable characteristics. We also 
estimated multilevel regression models that clustered hospital inpatient visits 
across physicians. We then repeated our linear regression analysis focusing 
separately on physicians working only in either teaching or non-teaching 
hospitals to address possible endogeneity of patient case mix and unobservable 
physician-specific factors that may not be completely addressed via regression 
models. Finally, we re-estimated our multilevel model using all hospital 
inpatient stays registered to two subsamples of physicians based on their 
observable characteristics by employing propensity score nearest-neighbor (NN) 
matching without replacement. RESULTS: Our key findings remained the same 
across all estimations: 1) the costs of hospital inpatient stays registered to female 
physicians or foreign-trained physicians are significantly lower than the costs of 
hospital stays registered to male physicians or U.S.-trained physicians; 2) the 
costs of hospital stays registered to physicians with more experience is lower 
when compared to physicians with less experience; and 3) there is substantial 
variation in costs of hospital inpatient stays across board certified physician 
specialties, where surgeons and cardiologists are generally associated with 
higher costs of hospital inpatient stays. CONCLUSIONS: Our findings 
demonstrate that physicians’ characteristics have a significant impact on the 
costs of hospital inpatient stays.  
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OBJECTIVES: This study empirically investigates “medical litigations” against 
physicians to assess its impact on hospital inpatient costs registered to 
physicians facing medical litigations and the spillover effects on other physician 
colleagues. METHODS: We employ generalized linear models to estimate the 
impact of the medical litigation against an individual physician on hospital 
inpatient costs. We also estimate the spillover effects of the medical litigation 
against an individual physician on the costs of hospital inpatient stays registered 
to other physicians with no medical litigation history practicing within the same 
hospitals for each of the following board certified physician specialty groups: 
Cardiologists, general practitioners, neurologists, obstetricians and/or 
gynecologists, pediatricians, psychologists, surgeons, and urologists. We use the 
Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases (SID), 
the American Hospital Association Annual Survey Database, and the Area 
Resource File in this analysis. Our hospital data for 2008 are drawn from Florida, 
and physician information was obtained from the state’s medical board where 
we use physicians’ license numbers to register each hospital inpatient visit to a 
